Chronic Myelogenous Leukemia News and Research

Latest Chronic Myelogenous Leukemia News and Research

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

Teva's SYNRIBO for injection receives FDA approval for home administration

Teva's SYNRIBO for injection receives FDA approval for home administration

NCCN publishes new patient resource for stage 0 breast cancer

NCCN publishes new patient resource for stage 0 breast cancer

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

FDA grants full approval of SYNRIBO for injection

FDA grants full approval of SYNRIBO for injection

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Dasatinib+letrozole improves survival for women with hormone receptor-positive, HER2-negative metastatic breast cancer

Dasatinib+letrozole improves survival for women with hormone receptor-positive, HER2-negative metastatic breast cancer

Phase 1/2 clinical trial data for VAL-083 in glioblastoma is presented at 18th Annual SNO meeting

Phase 1/2 clinical trial data for VAL-083 in glioblastoma is presented at 18th Annual SNO meeting

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Delmar Pharmaceuticals announces quarterly update, strengthens intellectual property portfolio

Delmar Pharmaceuticals announces quarterly update, strengthens intellectual property portfolio

Scientists investigate combined action of two different compounds against CML

Scientists investigate combined action of two different compounds against CML

Study shows ABL kinases have enhanced expression and activity in CML

Study shows ABL kinases have enhanced expression and activity in CML

Cancer-linked mitosis: an interview with Professor Scott Kern, Johns Hopkins University School of Medicine

Cancer-linked mitosis: an interview with Professor Scott Kern, Johns Hopkins University School of Medicine

Mouse study shows leukemia halts accumulation of toxic proteins linked to Parkinson's disease

Mouse study shows leukemia halts accumulation of toxic proteins linked to Parkinson's disease

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

Scientists develop new cancer immunotherapy treatment for children with high-risk solid tumors

Scientists develop new cancer immunotherapy treatment for children with high-risk solid tumors

European Commission grants conditional marketing authorization for Pfizer's BOSULIF

European Commission grants conditional marketing authorization for Pfizer's BOSULIF

Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences